Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
Date:8/7/2008

patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.373.0171 or visit http://www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the adequacy of our capital resources to fund our operations. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to successfully develop new formulations and complete research and development, including pre-clinical and clinical studies, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products. And we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at http://www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. China Biopharma, Inc. Announces New Plan of Operation
5. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
6. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... --  Intrexon Corporation (NYSE: XON ) today ... 2015 financial results after the market closes on Monday, ... a conference call at 5:30 PM ET to discuss ... The conference call may be accessed by dialing ... join the "Intrexon Corporation Call."  Participants may also access ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces the compact, ... of analytical laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an ... and maintenance-free solution for a broad range of vacuum filtration applications. , Featuring ...
(Date:7/31/2015)... KONG , July 31, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... the U.S. Securities and Exchange Commission. The filed Form ... ended March 31, 2015. The Form 20-F can be ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Sterlitech Launches New Line of Vacuum Pumps 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... ATLANTA, May 1 CryoLife, Inc., (NYSE: ... company, announced today,that Harvey Morgan has been elected ... Morgan is a Managing Director at Bentley,Associates L.P., ... more than 35 years of investment banking experience ...
... 1 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin ... leading manufacturer and distributor in China of ... medical industry and,glucose and starch products for ... appointment of Ms. Melody Shi as its ...
... Therapeutics (Amex:,CXM) announced today that Richard A. Schatz, M.D., ... early pioneer of coronary stent,technology and is best known ... Palmaz-Schatz stent. Dr. Schatz is Research Director of,Cardiovascular Interventions ... in La Jolla, California. He is also active in ...
Cached Biology Technology:Harvey Morgan Joins CryoLife Board of Directors 2Shengtai Pharmaceutical, Inc. Appoints New CFO 2Shengtai Pharmaceutical, Inc. Appoints New CFO 3Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board 2Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board 3Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board 4
(Date:7/21/2015)... July 21, 2015 Today, ZTE announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... leading smartphone manufacturer in China and we ... 02 5 for Axon , ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... York City/Great Neck, NY) The Brain & Behavior ... Research on Schizophrenia and Depression) has announced approximately $4 ... has invested close to $300 million in research to ... for mental illness. From about 500 applicants, forty ...
... pathogen that causes Lyme Diseaseunlike any other known organismcan ... needs to make proteins and enzymes. Instead of iron, ... thus eluding immune system defenses that protect the body ... Borrelia burgdorferi requires unusually high levels of ...
... researchers have taken an important step in the ongoing battle ... a breakthrough device that can immediately detect the presence of ... lighter than a cellphone and about the size of a ... measure nicotine in the air. A sensor chip then records ...
Cached Biology News:Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 2Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 3Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 4Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 5Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 6Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 7Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 8Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 9Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 10Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 11Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 12Scientists reveal quirky feature of Lyme disease bacteria 2Scientists reveal quirky feature of Lyme disease bacteria 3Scientists create new tools for battling secondhand smoke 2Scientists create new tools for battling secondhand smoke 3
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: